Compare Rockwell Automation (ROK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Zoetis Inc — how do they compare? Rockwell Automation trades at $450.55 (market cap $49.64B), while Zoetis Inc trades at $72.54 (market cap $31.14B). The key difference: Rockwell Automation is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| ROK | ZTS | |
|---|---|---|
Market Cap | $49.64B | $31.14B |
Sector | Industrials | Health |
52-Week High | $495.08 | $156.76 |
52-Week Low | $333.75 | $71.91 |
Enterprise Value | $52.77B | $38.70B |
Dividend Yield | 1.23% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $450.36, up 3.48% today, with a neutral technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.49, exceeding expectations, and raised full-year guidance amid robust demand in automation markets. Valuation ratios are elevated with a P/E of 41.85, but profitability remains solid with a net income margin of 13.38%.
Outlook is positive due to consistent earnings outperformance and AI-driven growth initiatives, though high valuation and inflationary cost pressures present risks. The consensus price target of $507.00 implies potential upside, supported by a majority analyst hold rating reflecting cautious optimism.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
